# A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

> **NCT04044690** · PHASE3 · TERMINATED · sponsor: **CSL Behring** · enrollment: 134 (actual)

## Conditions studied

- Dermatomyositis

## Interventions

- **DRUG:** human immunoglobulin G
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04044690
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-21
- **Primary completion:** 2024-12-02
- **Final completion:** 2024-12-02
- **Target enrollment:** 134 (ACTUAL)
- **Why stopped:** Primary endpoint not attained
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04044690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04044690, "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04044690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*